Eliem Therapeutics Performance
| ELYMDelisted Stock | USD 3.04 0.04 1.30% |
The firm shows a Beta (market volatility) of -1.27, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Eliem Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Eliem Therapeutics is expected to outperform it. At this point, Eliem Therapeutics has a negative expected return of -1.18%. Please make sure to confirm Eliem Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Eliem Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit | 09/11/2024 |
2 | Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3 | 09/20/2024 |
3 | 500,000 Shares in Eliem Therapeutics, Inc. Acquired by Ally Bridge Group NY LLC - MarketBeat | 09/24/2024 |
4 | ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN | 11/20/2024 |
| Begin Period Cash Flow | 43.6 M |
Eliem |
Eliem Therapeutics Relative Risk vs. Return Landscape
If you would invest 683.00 in Eliem Therapeutics on September 1, 2024 and sell it today you would lose (379.00) from holding Eliem Therapeutics or give up 55.49% of portfolio value over 90 days. Eliem Therapeutics is currently does not generate positive expected returns and assumes 4.8638% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Eliem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eliem Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eliem Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eliem Therapeutics, and traders can use it to determine the average amount a Eliem Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2418
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELYM |
Estimated Market Risk
| 4.86 actual daily | 43 57% of assets are more volatile |
Expected Return
| -1.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eliem Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eliem Therapeutics by adding Eliem Therapeutics to a well-diversified portfolio.
Eliem Therapeutics Fundamentals Growth
Eliem Stock prices reflect investors' perceptions of the future prospects and financial health of Eliem Therapeutics, and Eliem Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eliem Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Cash And Equivalents | 122.95 M | |||
| Cash Per Share | 4.63 X | |||
| Total Debt | 349 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 3.33 X | |||
| Cash Flow From Operations | (20.6 M) | |||
| Earnings Per Share | (2.22) X | |||
| Total Asset | 110.47 M | |||
| Retained Earnings | (155.98 M) | |||
About Eliem Therapeutics Performance
By examining Eliem Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Eliem Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Eliem Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. Eliem Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Things to note about Eliem Therapeutics performance evaluation
Checking the ongoing alerts about Eliem Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eliem Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eliem Therapeutics is now traded under the symbol CLYM. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Eliem Therapeutics generated a negative expected return over the last 90 days | |
| Eliem Therapeutics has high historical volatility and very poor performance | |
| Eliem Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN |
- Analyzing Eliem Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eliem Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Eliem Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eliem Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eliem Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eliem Therapeutics' stock. These opinions can provide insight into Eliem Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |